# Re-evaluation Task: HN3-004

## Context
- **Case ID**: HN3-004
- **Cancer type**: HPV-Negative Tonsillar Squamous Cell Carcinoma
- **Stage**: T3N2bM0, Stage IVA (AJCC 8th edition, p16-negative staging)
- **Molecular profile**: HPV-negative (p16-negative), CCND1 amplified, TP53 mutated, EGFR overexpression likely (common in HPV-negative HNSCC)
- **Report file**: experiment_reports\HN3-004_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The most critical gaps in the report are the lack of data on Pembrolizumab Monotherapy (KEYNOTE-048 Regimen) and Pembrolizumab + Platinum + 5-FU (KEYNOTE-048 Regimen), as these combinations are crucial for understanding the efficacy of pembrolizumab in various treatment regimens, which will improve the score by providing more comprehensive insights into immunotherapy's role in cancer treatment. Additionally, data on Carboplatin + Cetuximab + Radiation Therapy (Triple Therapy) is missing, which is a common and effective treatment approach for certain types of cancer, filling this gap will provide valuable information on the synergistic effects of these treatments.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  15/25  |  60.0% |
| tier_coverage                       |   8/10  |  80.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (60.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN3-004_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "HPV-Negative Tonsillar Squamous Cell Carcinoma",
    "stage": "T3N2bM0, Stage IVA (AJCC 8th edition, p16-negative staging)",
    "molecular_profile": [
      "HPV-negative (p16-negative)",
      "CCND1 amplified",
      "TP53 mutated",
      "EGFR overexpression likely (common in HPV-negative HNSCC)"
    ],
    "patient_demographics": {
      "age": 45,
      "sex": "Male"
    },
    "clinical_context": "HPV-negative tonsillar squamous cell carcinoma (T3N2bM0, Stage IVA) in a 45-year-old male with alcohol cardiomyopathy. HPV-negative status confers significantly worse prognosis than HPV-positive oropharyngeal cancer, with 5-year disease-free survival <50%. Alcohol cardiomyopathy is a critical comorbidity: cisplatin is relatively contraindicated due to cardiotoxicity risk (heart failure, arrhythmias, hypomagnesemia-induced cardiac events). Cisplatin causes direct myocardial injury via oxidative stress and mitochondrial dysfunction, which can exacerbate existing cardiomyopathy. Cetuximab plus radiation is the NCCN-recommended alternative for cisplatin-ineligible patients per NRG-HN004 results. Carboplatin (AUC 1.5-2 weekly) is a reduced-cardiotoxicity platinum option. CCND1 amplification is a targetable alteration via CDK4/6 inhibitors (palbociclib, dalpiciclib); the CDK4/6i + cetuximab combination has shown promising activity in HPV-negative HNSCC. TP53 mutation (75-85% of HPV-negative HNSCC) is associated with worse prognosis, radioresistance, and reduced sensitivity to anti-PD-1 monotherapy. Cardiology co-management with serial echocardiography and BNP monitoring is mandatory throughout treatment. KEYNOTE-048 established pembrolizumab-based therapy as first-line for recurrent/metastatic disease. KEYNOTE-689 established perioperative pembrolizumab for resectable locally advanced disease."
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Cetuximab + Radiation Therapy (Bioradiotherapy)",
      "category": "Standard of Care",
      "composite_rating": 7.8,
      "rating_breakdown": {
        "evidence_level": {
          "score": 8,
          "rationale": "Phase 3 RCT (Bonner et al., NEJM 2006) demonstrated OS benefit of cetuximab+RT vs RT alone in locally advanced HNSCC. NRG-HN004 Phase 2/3 confirmed cetuximab+RT remains standard for cisplatin-ineligible patients (2-year PFS 63.7% vs 50.6% durvalumab+RT). NCCN Category 1 recommendation for cisplatin-ineligible patients."
        },
        "survival_benefit": {
          "score": 7,
          "rationale": "Bonner trial: median OS 49.0 vs 29.3 months (HR 0.74). 5-year OS 45.6% vs 36.4%. However, HPV-negative patients derive less benefit than HPV-positive. For cisplatin-ineligible patients with cardiomyopathy, this is the most effective available definitive treatment. NRG-HN004 2-year OS 78% with cetuximab+RT."
        },
        "accessibility": {
          "score": 9,
          "rationale": "Cetuximab is FD
... (truncated — read full file from experiment_reports\HN3-004_report.json)
```
